Molecular group:
Other leucocyte cell surface receptors and membrane transporters
Molecule/Cell:
PD-L1/LAG-3
Plasmodium strain:
Plasmodium yoelii 17XNL
pRBC infection titer:
10^5
Mouse genetic background (Con):
C57BL/6
Experimental treatment group (EG):
anti-PD-L1 + anti-LAG-3
Lethal infection (Con):
no
Lethal infection (EG):
no
Pathology (Con):
N.I.
Pathology (EG):
N.I.
Parasitemia (EG vs Con):
Decreased
Additional phenotypes (EG vs Con):
PD-L1 and LAG-3 synergistically decrease parasitemia; ↑ numbers of splenic parasite-specific CD4+ and CD8+ T cells, IFN-g+TNF+ and IFN-g+IL-2+ parasite-specific CD4+ and CD8+ T cells, follicular CD4+ T cells, plasmablasts, CD19+B220+ B cells, PNA+ germinal-center B cells; improved splenic architecture with preservation of IgM+ B cell follicles and enhanced PNA+ germinal center formation; ↑ titers of MSP-1(19)-specific IgGs after immunization with a human malaria vaccine candidate MSP-1(19); ↑ parasite clearance in mice recieving serum from PD-L1 and LAG-3 depleted mice when mice were challenged with P. yoelii
Refs:
Butler et al., 2012, Nat Immunol
Hyperlink: